CGRP Seen as a Game-Changer in Migrane - Wells Fargo Cleveland Clinic Event

October 6, 2016 1:33 PM EDT
Get Alerts ALDR Hot Sheet
Price: $21.45 -0.69%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 18 | New: 19
Trade ALDR Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Wells Fargo analyst David Maris issued another note from the firm's Hot Topics in Healthcare at the Cleveland Clinic. Maris notes that at the event Dr. Jennifer Kreigler said CGRP could be a game-changer for migraine patients.

Kreigler estimates that approximately 28 million Americans suffer from migraines and estimates that loss of productivity from migraine sufferers costs the U.S. economy $13-15 billion annually, providing some clues for the potential economic opportunity of CGRP candidates.

The first CGRP to market could get an outsized share, as physicians gain familiarity with the new class, although dosing
frequency and convenience are likely to drive it further.

While the analyst didn't name names, some companies working on CGRP migraine drugs included: Alder BioPharma (NASDAQ: ALDR), Amgen (NASDAQ: AMGN), Eli Lilly (NYSE: LLY), and Teva (NASDAQ: TEVA).



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Related Entities

Wells Fargo, David Maris

Add Your Comment